These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 10652560

  • 21. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
    Jiborn T, Abrahamson M, Gadaleanu V, Lundwall A, Bjartell A.
    BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
    [Abstract] [Full Text] [Related]

  • 22. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
    Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H.
    J Urol; 2004 May; 171(5):1855-60. PubMed ID: 15076293
    [Abstract] [Full Text] [Related]

  • 23. Expression of early growth response genes in human prostate cancer.
    Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ.
    Cancer Res; 1998 Jun 01; 58(11):2461-8. PubMed ID: 9622090
    [Abstract] [Full Text] [Related]

  • 24. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.
    Clin Cancer Res; 2005 Sep 15; 11(18):6582-8. PubMed ID: 16166436
    [Abstract] [Full Text] [Related]

  • 25. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.
    J Urol; 2001 Dec 15; 166(6):2193-7. PubMed ID: 11696734
    [Abstract] [Full Text] [Related]

  • 26. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H.
    J Urol; 2001 Jan 15; 165(1):119-25. PubMed ID: 11125379
    [Abstract] [Full Text] [Related]

  • 27. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.
    Br J Cancer; 2002 Sep 23; 87(7):726-8. PubMed ID: 12232754
    [Abstract] [Full Text] [Related]

  • 28. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 29. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM, Koch MO, Eble JN, Lin H, Cheng L.
    J Urol; 2006 May 01; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [Abstract] [Full Text] [Related]

  • 30. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R.
    J Urol; 2001 Sep 01; 166(3):851-5. PubMed ID: 11490232
    [Abstract] [Full Text] [Related]

  • 31. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 32. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
    Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K.
    J Urol; 2006 Oct 01; 176(4 Pt 1):1387-91. PubMed ID: 16952639
    [Abstract] [Full Text] [Related]

  • 33. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
    Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM.
    Cancer Res; 2006 Nov 15; 66(22):10683-90. PubMed ID: 17108105
    [Abstract] [Full Text] [Related]

  • 34. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
    Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z.
    J Urol; 2001 Dec 15; 166(6):2171-7. PubMed ID: 11696729
    [Abstract] [Full Text] [Related]

  • 35. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
    Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA, Shappell SB.
    Hum Pathol; 2000 Sep 15; 31(9):1146-54. PubMed ID: 11014584
    [Abstract] [Full Text] [Related]

  • 36. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z, Wenlu S.
    Prostate; 2008 Feb 01; 68(2):190-9. PubMed ID: 18076024
    [Abstract] [Full Text] [Related]

  • 37. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH, Lee S, Lee HJ, Hwang KS.
    J Pathol; 2004 Feb 01; 202(2):233-40. PubMed ID: 14743506
    [Abstract] [Full Text] [Related]

  • 38. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
    Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, Gleason DF.
    Anat Rec; 1996 Aug 01; 245(4):652-61. PubMed ID: 8837723
    [Abstract] [Full Text] [Related]

  • 39. Cathepsin B and its inhibitor stefin A in brain tumors.
    Strojnik T, Zajc I, Bervar A, Zidanik B, Golouh R, Kos J, Dolenc V, Lah T.
    Pflugers Arch; 2000 Aug 01; 439(3 Suppl):R122-3. PubMed ID: 10653164
    [Abstract] [Full Text] [Related]

  • 40. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.